Thrombomodulin/BDCA-3 Antibody (501727) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: WB, IP
• Clone: 501727
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

Thrombomodulin/BDCA-3 Antibody (501727) [Alexa Fluor® 700] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Thrombomodulin/BDCA-3
  Ala19-Ser515
  Accession # P07204(Val473)
• Specificity: Detects human Thrombomodulin/BDCA-3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse Thrombomodulin is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Thrombomodulin/BDCA-3 Antibody (501727) [Alexa Fluor® 700]

• BDCA3
• BDCA-3
• CD141 antigen
• CD141
• Fetomodulin
• THBD
• THRM
• Thrombomodulin
• TM

Background

Encoded by the THBD gene, Thrombomodulin is also known as blood dendritic cell antigen 3 (BDCA‑3) and designated CD141. The deduced amino acid (aa) sequence of human THBD predicts a signal peptide (aa 1‑18) and a mature chain (aa 19‑575) that consists of following domains: C‑type lectin (aa 31‑169), EGF‑like (aa 241‑281, aa 284‑324, aa 325‑363, aa 365‑405, aa 404‑440, and aa 441‑481), transmembrane (aa 516 to 539) and cytoplasmic (aa 540‑575). The region used as an immunogen consists of aa 19‑515, corresponding to the extracellular portion of the type I membrane protein. Predominantly synthesized by vascular endothelial cells, THBD inhibits coagulation and fibrinolysis (1‑3). It functions as a cell surface receptor and an essential cofactor for active thrombin, which in turn activates protein C and thrombin‑activatable fibrinolysis inhibitor (TAFI), also known as carboxypeptidase B2 (CPB2). Activated protein C (APC), facilitated by protein S, degrades coagulation factors Va and VIIIa, which are required for thrombin activation. Activated CPB2 cleaves basic C‑terminal aa residues of its substrates, including fibrin, preventing the conversion of plasminogen to plasmin. In addition, THBD gene polymorphisims are associated with human disease and THBD plays a role in thrombosis, stroke, arteriosclerosis, and cancer (4). For example, increased serum levels of THBD, due to protease cleavage, have been associated with smoking, cardiac surgery, atherosclerosis, liver cirrhosis, diabetes mellitus, cerebral and myocardial infarction, and multiple sclerosis (5).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.